Navigation Links
960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter
Date:3/18/2008

Angiotech's 5-FU coated catheter over existing devices.

In addition to meeting the non-inferiority endpoint, these data show a trend toward superiority for the 5-FU coated catheter over the market leading device, both in frequency and nature of colonizations and infections. This efficacy comes without the public health risk that accompanies the long-term, low level exposure to important anti-microbials such as chlorhexidine and silver sulfadiazine or antibiotics like rifampin. Angiotech's ground breaking 5-FU technology achieves improved anti-infective performance without the risk of clinically meaningful bacterial or fungal resistance, a unique property among anti-infective coatings.

"We are extremely pleased with the clinical results of the 5-FU CVC trial. Achieving zero percent blood stream infection bodes well for a most vulnerable patient population and has very positive implications for the expansion of our 5-FU anti-infective platform. To observe substantial anti-infective performance without exposure to antiseptics or antibiotics is very important to all clinicians, especially infectious disease and infection control experts," said Dr. William Hunter, President and CEO of Angiotech.

Angiotech submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for its 5-FU CVC in December 2007 and is finalising commercialization plans for the product.

About the Study

This study was a multi-center (25 U.S. sites), randomized clinical trial conducted to compare the efficacy of our novel 5-FU-eluting CVC to a CH-SS coated CVC in preventing catheter colonization, local site infection and CRBSI.

About CVC and Catheter-Related Infections

Central venous catheters are usually inserted into critically ill patients for extended periods of time to administer fluids, drugs, and nutrition, as well as facilitate frequent blood draws. One of the complications associated with CVC implantation is infection, which can
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... -- China Cord Blood Corporation (NYSE: CO ) ... results for the first quarter of fiscal year 2015 ... the US.  The Company will host ... August 29, 2014 to discuss its financial performance and ... followed by a question and answer session.  Interested parties ...
(Date:8/21/2014)... Gallus BioPharmaceuticals , LLC, ... manufacturing organization (CMO) announced today that it has ... company focused on the development of innovative approaches ... anti-prostate specific membrane antigen (PSMA) monoclonal antibody used ... the agreement the antibody will be produced in ...
(Date:8/20/2014)... of patented university inventions licensed to biotechnology firms ... commercialization. To open these roadblocks, the researchers suggest ... the discovery stage could lead to faster commercialization ... derived from discoveries made in university laboratories and ... during clinical trials, which have a high failure ...
(Date:8/20/2014)... 2014 High performance computing (HPC) ... most complete climate and Earth system model to ... issues. , Eight national laboratories, including Lawrence ... Center for Atmospheric Research, four academic institutions and ... participating national laboratories include Argonne, Brookhaven, Lawrence Berkeley, ...
Breaking Biology Technology:China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3
... is pleased to announce the,never- before assembly of ... Lighting the Onco-Pipeline -- Innovations in Stem Cell,Biomarker, ... in Tampa,Florida. iiBIG is particularly pleased to join ... Florida, University of Florida, Shands,Cancer Center, Scripps Florida, ...
... Ultra-Fine Beam Shaping Device Optimized for Targeting ... Stereotactic Radiotherapy and Radiosurgery, PALO ALTO, ... (NYSE: VAR ) has received FDA ... (MLC), an ultra-fine beam shaping,device for radiosurgery. ...
... Morria Biopharmaceuticals Plc, a,private biopharmaceutical company ... today that it has,appointed Rosemary Mazanet M.D., ... Mazanet has significant experience in both executive ... Dr. Mazanet serves on the Board of ...
Cached Biology Technology:Lighting the Onco-Pipeline, Stem Cell Cancer, and More at Global Cancer Congress, January 28-29, 2008, Tampa 2Lighting the Onco-Pipeline, Stem Cell Cancer, and More at Global Cancer Congress, January 28-29, 2008, Tampa 3Varian Medical Systems Receives FDA 510(k) Clearance for High-Definition Collimator That Enables Ultra-Fine Intensity-Modulated Radiosurgery 2Varian Medical Systems Receives FDA 510(k) Clearance for High-Definition Collimator That Enables Ultra-Fine Intensity-Modulated Radiosurgery 3Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer 2
(Date:8/21/2014)... the pancreas digesting itself resulting in severe abdominal pain, ... around 20,000 patients are diagnosed with the disease resulting ... treatment is restricted to intravenous fluid and nutritional support. ... Life Sciences, who led the research, said "The major ... stones and excessive alcohol intake combined with a high ...
(Date:8/20/2014)... , Aug. 20, 2014 /CNW/ -  Issue ... and can quickly become life threatening for some children.    ... as 1.2 million Canadians have food allergies and this number ... cent of children are estimated to have food allergies.  ... mild skin irritations and hives to breathing difficulties and loss ...
(Date:8/20/2014)... of Health has awarded the Oklahoma Medical Research Foundation ... on anthrax and the bacteria,s effects on humans. ... and his colleagues have studied the human immune response ... for Human Immunology. The original funding came soon after ... heels of the terrorist attacks of Sept. 11, 2001. ...
Breaking Biology News(10 mins):Insulin offers new hope for the treatment of acute pancreatitis 2Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3$14.5 million grant awarded to continue anthrax studies 2
... United States, African Americans have approximately twice the risk ... a similar prevalence in earlier stages of chronic kidney ... (GW) researcher Dominic Raj, M.D., identifies factors that mediate ... black patients and white patients, as well as among ...
... range-wide assessment of the bonobo (formerly known as the ... known and endangered great ape is quickly losing space ... of usable habitat is attributed to both forest fragmentation ... of Georgia, University of Maryland, the Wildlife Conservation Society, ...
... University School of Medicine (BUSM) and Boston Medical Center ... initiative funded by the Bill & Melinda Gates Foundation. ... BMC, and Ducksoo Kim, MD, professor of radiology at ... fellowship at BMC, will use nanotechnology to develop a ...
Cached Biology News:Genetics contribute to increased risk for end-stage renal disease for African Americans with CKD 2Study finds the forgotten ape threatened by human activity and forest loss 2Study finds the forgotten ape threatened by human activity and forest loss 3BUSM/BMC receives Grand Challenges Explorations grant to develop next generation condom 2BUSM/BMC receives Grand Challenges Explorations grant to develop next generation condom 3
... Custom monoclonal antibody development to targets including ... molecules, DNA, and cancer-specific surface antigens. ... and is completed in approximately 40 days ... nature of antigens). Phase I: Immunization, ...
... Clone/PAD: ZMD.460. Immunogen: Synthetic peptide ... human C35 protein (chromosome 17 open reading ... Specific for the C35 protein. On ... at ~15 kDa band. Reactivity: Human ...
... Peptide sequences: Two separate ... corresponding to the same sequence used ... antiserum (Catalog No. 160890) ... with Cayman's guanylate cyclase polyclonal antiserum ...
Immunogen: Secretory component isolated from human colostrum. Storage: 4 C...
Biology Products: